HDFC Mutual Fund launches HDFC Pharma and Healthcare Fund. Should you invest?
HDFC Mutual Fund has launched HDFC Pharma and Healthcare Fund, an open-ended equity scheme investing in pharma and healthcare companies.
The new fund offer or NFO of the scheme is open for subscription and it will close on September 28. The scheme will re-open for continuous sale and repurchase within five business days from the date of allotment of units under NFO.
The investment objective of the scheme is to provide long-term capital appreciation by investing predominantly in equity and equity-related securities of pharma and healthcare companies.
Best MF to invest
Looking for the best mutual funds to invest? Here are our recommendations.
View Details»
The performance of the scheme will be benchmarked against S&P BSE Healthcare Index. The scheme will be managed by Nikhil Mathur, Dhruv Muchhal (overseas investments).
The scheme will offer both regular and direct plans with growth and IDCW options. The minimum application amount for purchase and switches is Rs 100 and any amount thereafter.
The scheme will invest 80-100% in equity and equity related instruments of pharma and healthcare companies, 0-20% in equity and equity related instruments of companies other than pharma and healthcare companies, 0-10% in units of REITs and InvITs, 0-20% in debt securities, money market instruments and fixed income derivatives, and 0-20% in units of mutual fund.
The scheme will follow a bottom-up approach to stock-picking and choose companies which are expected to derive benefit from growth in the pharma and healthcare segment.
The scheme is suitable for investors who are seeking to generate long-term capital appreciation and want investment predominantly in equity and equity related instruments of pharma and healthcare companies.
Should
